Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up

Autor: Henk G. van der Poel, Wouter Kroese, Pim J. van Leeuwen, Daan de Bruin, Erik van Muilekom, Kurdo Barwari, Nikolaos Grivas, Esther Wit, Corinne Tillier
Přispěvatelé: Urology, Biomedical Engineering and Physics, CCA - Cancer Treatment and Quality of Life, CCA - Imaging and biomarkers, ACS - Atherosclerosis & ischemic syndromes
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Microbiology (medical)
Biochemical recurrence
medicine.medical_specialty
medicine.medical_treatment
Clinical Biochemistry
Urology
Sensitivity and Specificity
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Robotic Surgical Procedures
biochemical recurrence
Humans
prostate-specific antigen
Immunology and Allergy
Medicine
Research Articles
Retrospective Studies
prostatectomy
business.industry
Prostatectomy
Biochemistry (medical)
Public Health
Environmental and Occupational Health
Prostatic Neoplasms
Retrospective cohort study
Hematology
Odds ratio
Middle Aged
Prognosis
medicine.disease
predictive value of tests
Medical Laboratory Technology
Prostate-specific antigen
030104 developmental biology
030220 oncology & carcinogenesis
Predictive value of tests
Positive Surgical Margin
business
Zdroj: Journal of clinical laboratory analysis, 33(2):e22693. Wiley-Liss Inc.
Grivas, N, de Bruin, D, Barwari, K, van Muilekom, E, Tillier, C, van Leeuwen, P J, Wit, E, Kroese, W & van der Poel, H 2019, ' Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up ', Journal of clinical laboratory analysis, vol. 33, no. 2, e22693 . https://doi.org/10.1002/jcla.22693
ISSN: 0887-8013
DOI: 10.1002/jcla.22693
Popis: Background: Ultrasensitive prostate-specific antigen (USPSA) is useful for stratifying patients according to their USPSA-based risk. Aim of our study was to determine the usefulness of USPSA as predictor of biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP). Methods: This retrospective study included 213 prostate cancer patients who had a postoperative USPSA between 0.01 and 0.2 ng/mL and at least 2 years of follow-up. We developed predictive models for BCR with PSA ≥0.2 and ≥0.5 ng/mL. Results: A total of 103 patients (48.3%) had BCR at a median follow-up of 13.3 months. Higher postoperative USPSA (odds ratio [OR] = 4.73, P
Databáze: OpenAIRE
Externí odkaz: